公开(公告)号：MX2009005252A

公开(公告)日：2009-05-28

申请号：MX2009005252

申请日：2007-11-16

Applicant: ABBOTT LAB

Inventor： WANG LU ,  WISHART NEIL ,  DIXON RICHARD W ,  LI BIQIN ,  GEORGE DAWN M ,  WU XIAOYUN ,  FRIEDMAN MICHAEL ,  HOBSON ADRIAN

IPC: C07D471/04 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/454 ,  C07D401/04

Abstract: La presente invención está dirigida a aminopirrolidinas novedosas de la fórmula (I), sales farmacéuticamente aceptables de las mismas, metabolitos de las mismas, isómeros de las mismas, estereoisómeros de las mismas o pro-fármacos de las mismas, en donde las variables son como se definen en la presente. Los compuestos de la fórmula (I) son útiles como antagonistas del receptor de quimiocina y como tales serian útiles en el tratamiento de ciertas condiciones y enfermedades, especialmente condiciones y enfermedades inflamatorias y trastornos y condiciones proliferativos, por ejemplo, cánceres.

公开(公告)号：DOP2009000033A

公开(公告)日：2009-03-15

申请号：DO2009000033

申请日：2009-03-04

Applicant: ABBOTT LAB

Inventor： WU CHENGBIN ,  DIXON RICHARD W ,  BELK JONATHAN P ,  YING HUA ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  HINTON PAUL R ,  KUMAR SHANKAR ,  MELIM TERRY L ,  CHEN YAN

Abstract: Proteínas de unión a !L-13. Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIL-13 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antigeno del mismo. Tambien se provee un método de elaboración y un método de uso de los anticuerpos de la invención. Los anticuerpos, o porciones de anticuerpo, de la invención son de utilidad para detectar la hIL-13 y para inhibir la actividad hIL-13, por ejemplo, en un sujeto humano que sufre de un trastorno en el cual la actividad de la hIL-13 sea perjudicial.

公开(公告)号：BRPI0611714A2

公开(公告)日：2009-01-13

申请号：BRPI0611714

申请日：2006-06-29

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K14/715

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

公开(公告)号：CA2669917A1

公开(公告)日：2008-05-22

申请号：CA2669917

申请日：2007-11-16

Applicant: ABBOTT LAB

Inventor： GEORGE DAWN M ,  WISHART NEIL ,  DIXON RICHARD W ,  LI BIQIN ,  HOBSON ADRIAN ,  FRIEDMAN MICHAEL ,  WANG LU ,  WU XIAOYUN

IPC: C07D401/04 ,  A61K31/438 ,  A61K31/517 ,  C07D401/14

Abstract: The present invention is directed to novel aminopyrrolidines of formula ( I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables a re as defined herein. The compounds of formula (I) are useful as chemokine r eceptor antagonists and as such would be useful in treating certain conditio ns and diseases, especially inflammatory conditions and diseases and prolife rative disorders and conditions, for example, cancers.

公开(公告)号：CA2644910A1

公开(公告)日：2007-10-18

申请号：CA2644910

申请日：2007-04-02

Applicant: ABBOTT LAB

Inventor： ABBOTT LILY K ,  CUSACK KEVIN P ,  ARGIRIADI MARIA A ,  CALDERWOOD DAVID J ,  ZHANG XIAOLEI ,  MULLEN KELLY D ,  DIXON RICHARD W ,  GORDON THOMAS D ,  TALANIAN ROBERT V ,  WANG LU X ,  LI BIQIN ,  WU XIAOYUN ,  FRANK KRISTINE E ,  BORHANI DAVID W ,  ERICSSON ANNA M ,  BURCHAT ANDREW ,  WISHART NEIL ,  BARBERIS CLAUDE E

IPC: A61K31/5377

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

公开(公告)号：AU2006283532A1

公开(公告)日：2007-03-01

申请号：AU2006283532

申请日：2006-08-18

Applicant: ABBOTT LAB

Inventor： SALFELD JOCHEN G ,  DIXON RICHARD W ,  WU CHENGBIN ,  GHAYUR TARIQ

IPC: A61K49/00 ,  A61K31/192 ,  A61K31/343 ,  A61K31/365 ,  A61K31/4152 ,  A61K31/445 ,  A61K31/496 ,  A61K31/551 ,  A61K31/60 ,  A61K39/395

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

公开(公告)号：NZ520392A

公开(公告)日：2005-04-29

申请号：NZ52039201

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  C12N15/02 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: An isolated human monoclonal antibody capable of binding to human IL-18 is described. The antibody can be used in the manufacture of a medicament for inhibiting human IL-18 activity, and for detecting human IL-18 activity in a sample.

公开(公告)号：PL356836A1

公开(公告)日：2004-07-12

申请号：PL35683601

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  C12N15/02 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C12N15/13

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：CA2399148A1

公开(公告)日：2001-08-16

申请号：CA2399148

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： WHITE MICHAEL ,  SHORROCK CELIA PATRICIA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  SALFELD JOCHEN ,  GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  A61P1/00 ,  A61P3/00 ,  A61P5/00 ,  A61P9/00 ,  A61P13/00 ,  A61P19/00 ,  A61P21/00 ,  A61P25/00 ,  A61K38/13 ,  C12N15/13 ,  A61K38/17 ,  A61K31/445 ,  A61K31/505 ,  A61K31/56 ,  C12N15/85

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particul ar antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutraliz e hIL-18 activityin vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject sufferin g from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：NZ596992A

公开(公告)日：2013-07-26

申请号：NZ59699206

申请日：2006-06-29

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: A61K39/395 ,  C07K14/715 ,  C07K16/00 ,  C07K16/24 ,  C12N15/13

Abstract: 596992 Disclosed is a binding protein that possesses an antigen binding domain, said binding protein capable of binding a p40 subunit of human IL-12, said antigen binding domain possessing six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein: CDR-H1 is: KSVMGVS, HIYWDDDKYYNPSLKS, RGIRSAMDY, KASQSVSNDVA, YASNRYT and QQDYNSPWT respectively.